Q1 2026 Moderna Inc Earnings Call Transcript
Key Points
- Moderna Inc (MRNA) reported significant year-over-year revenue growth to $0.4 billion, driven by strategic partnerships, particularly with the UK government.
- The company maintained a strong balance sheet with $7.5 billion in cash and investments, reflecting continued financial discipline.
- Moderna Inc (MRNA) achieved a milestone with the approval of mCOMBRIAX, the first flu plus COVID combo vaccine, in the European Union.
- The company secured approval for Spikevax in the European Union, which is expected to drive growth in the EU market in 2027.
- Moderna Inc (MRNA) advanced its oncology pipeline with the initiation of a Phase 3 clinical trial for intismeran in non-small cell lung cancer, expanding its focus on early-stage disease.
- Moderna Inc (MRNA) reported a net loss of $1.3 billion on a GAAP basis, primarily due to a litigation settlement with Arbutus and Genevant.
- The company's cost of sales increased significantly to $955 million, largely due to the $878 million litigation settlement.
- Revenue guidance for the second quarter is expected to be between $50 million and $100 million, indicating a potential slowdown compared to the first quarter.
- The company faces potential additional liability of up to $1.3 billion if it does not prevail in its appeal regarding the litigation settlement.
- Moderna Inc (MRNA) anticipates potential future declines in COVID vaccination rates, which could impact revenue growth.
Good day, and thank you for standing by. Welcome to Moderna's first quarter 2026 conference call. (Operator Instructions) Please be advised, today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Lavina Talukdar, Head of IR. Please go ahead.
Thank you, Kevin. Good morning, everyone, and thank you for joining us today to discuss Moderna's first quarter 2026 financial results and business updates. You can access the press release issued this morning as well as the slides that we'll be reviewing by going to the Investor section of our website.
On today's call are Stéphane Bancel, our Chief Executive Officer; Stephen Hoge, our President; and Jamey Mock, our Chief Financial Officer.
Please note that this conference call will include forward-looking statements made pursuant to the Safe Harbor provisions Private Securities Litigation Reform Act of 1995. Please see slide 2 of the accompanying presentation and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
